Malaria remains a significant contributor to the global burden of disease, with around 40% of
the world's population at risk of Plasmodium infections. The development of an effective …

Infections with Plasmodium falciparum and Plasmodium vivax cause over 600,000 deaths
each year, concentrated in Africa and in young children, but much of the world's population …

Ring-infected erythrocytes are the predominant asexual stage in the peripheral circulation
but are rarely investigated in the context of acquired immunity against Plasmodium …

Protective immunity to malaria depends on acquisition of parasite-specific antibodies, with
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) being one of the most …

Extreme diversity of the major Plasmodium falciparum antigen, PfEMP1, poses a barrier to
identifying targets of immunity to malaria. Here, we used protein microarrays containing …

Developing efficacious vaccines for human malaria caused by Plasmodium falciparum is a
major global health priority, although this has proven to be immensely challenging over the …

There are seven known species of Plasmodium spp. that can infect humans. The human
host can mount a complex network of immunological responses to fight infection and one of …

Introduction A vaccine would greatly accelerate current global efforts toward malaria
elimination. While a partially efficacious vaccine has been achieved for Plasmodium …

Background Protective malarial antibodies are acquired more rapidly in adults than children,
independently of cumulative exposure, however the cellular responses mediating these …

Background Antibodies to variant surface antigens (VSAs) such as Plasmodium falciparum
erythrocyte membrane protein 1 (PfEMP1) may vary with malaria severity. The influence of …